Avectas is a cell engineering technology company focused on revolutionizing the development of next-generation cell therapies. Its proprietary Solupore® platform enables the efficient, gentle, and scalable intracellular delivery of payloads (such as mRNA, DNA, proteins, and CRISPR-Cas9 RNP complexes) to primary cells for ex-vivo manufacturing. This technology aims to overcome the limitations of existing delivery methods, improving the efficacy, safety, and accessibility of advanced therapies for a range of diseases, including cancer and rare genetic disorders.
Global headquarters, research and development hub, strategic operations, and primary center for the innovation and advancement of Avectas's Solupore® cell engineering technology.
State-of-the-art laboratory facilities within a modern business campus, designed to support cutting-edge research in cell and gene therapy.
Avectas fosters a collaborative, innovative, and scientifically-driven work culture. Employees are focused on advancing cell therapy manufacturing and making a significant impact in biotechnology.
The Maynooth headquarters is central to Avectas's mission, housing its core R&D activities, intellectual property development, and global strategic management.
Avectas operates with a global outlook, anchored by its headquarters and technology center in Maynooth, Ireland, a manufacturing and operations facility in Dublin, Ireland, and a strategic US office in Cambridge, Massachusetts. The company actively engages in international partnerships and collaborations to make its Solupore® technology available to cell therapy developers worldwide, supporting the advancement of innovative treatments across different geographies.
Unit 310, Maynooth Business Campus
Maynooth
Co. Kildare
Ireland
Address: Unit 70, Block 71, The Plaza, Park West Business Park, Dublin 12, D12 N832, Ireland
Enhances Avectas's capacity for technology transfer, manufacturing scale-up, and operational support for European and global partners.
Address: 245 Main Street, Cambridge, MA 02142, USA
To drive growth and collaborations in the significant US cell and gene therapy market, fostering partnerships with pharmaceutical companies and research institutions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Avectas ' leadership includes:
Avectas has been backed by several prominent investors over the years, including:
Avectas has significantly strengthened its leadership team over the past 12-15 months with several strategic vice president and C-level appointments to support its growth and development of the Solupore® platform. No major executive departures have been publicly announced during this period.
Discover the tools Avectas uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Avectas primarily utilizes an email format consisting of the employee's first initial followed by their full last name, then '@avectas.com'. While this is the most commonly observed pattern, other formats may exist within the organization for specific roles or legacy reasons.
[first_initial][last]@avectas.com
Format
mmaguire@avectas.com
Example
85%
Success rate
Avectas Official Website • April 10, 2024
Avectas announced the strategic appointment of Daniel O’Mahony to the position of VP, Head of Engineering. He will be responsible for leading the company's engineering strategy, including the design and development of Avectas’ proprietary Solupore® cell engineering platform....more
Avectas Official Website • March 6, 2024
Avectas appointed Gillian Hendy as VP, Head of Business Development & Marketing. Gillian will lead Avectas’ business development and marketing strategy as the company advances its Solupore® non-viral cell engineering platform....more
EQT Group • May 10, 2023
Avectas, a cell engineering company, announced the completion of a EUR 30 million (USD 33 million) financing. The round was led by EQT Life Sciences, investing from its LSP ELSM Manco III L.P. fund, and existing investor Seamus Mulligan also participated. The funds will be used to accelerate the clinical translation and commercialization of Avectas' Solupore® technology platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Avectas , are just a search away.